{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:04:17Z","timestamp":1793289857111,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>Atherosclerotic cardiovascular disease (ASCVD) remains a leading global health challenge, with low-density lipoprotein (LDL) cholesterol a pivotal risk factor. While statins are cornerstone therapy for lowering LDL cholesterol, many high-risk primary prevention patients are unable to tolerate statin therapy and do not achieve their guideline directed LDL cholesterol goal. For these patients, non-statin therapies offer complementary and alternative approaches to LDL cholesterol reduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Recent advancements in non-statin therapies have expanded the options available to clinicians to lower LDL cholesterol in high-risk primary prevention patients. Yet these medications are often under-utilized in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Observational studies, Mendelian randomization studies, and randomized clinical trials support the role of non-statin LDL cholesterol lowering therapies in the primary prevention of ASCVD. This review summarizes the evidence supporting their use for the primary prevention of ASCVD and offers practical suggestions as to how clinicians can integrate these medications into their clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11883-025-01283-1","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:02:11Z","timestamp":1743750131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention"],"prefix":"10.1007","volume":"27","author":[{"given":"Chukwuemezie","family":"Kamanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean G.","family":"Karalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"1283_CR1","doi-asserted-by":"publisher","unstructured":"Martin SS, Aday AW, Almarzooq ZI, et al. Circulation. 2024;149(8):e347\u2013913. https:\/\/doi.org\/10.1161\/CIR.0000000000001209. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.","DOI":"10.1161\/CIR.0000000000001209"},{"issue":"4","key":"1283_CR2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amepre.2023.11.009","volume":"66","author":"RC Woodruff","year":"2024","unstructured":"Woodruff RC, Tong X, Khan SS, et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010\u20132022. Am J Prev Med. 2024;66(4):582\u20139. https:\/\/doi.org\/10.1016\/j.amepre.2023.11.009.","journal-title":"Am J Prev Med"},{"issue":"10059","key":"1283_CR3","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/s0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of Statin therapy. Lancet. 2016;388(10059):2532\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(16)31357-5.","journal-title":"Lancet"},{"key":"1283_CR4","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, NLA\/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25). https:\/\/doi.org\/10.1161\/cir.0000000000000625.","DOI":"10.1161\/cir.0000000000000625"},{"issue":"4","key":"1283_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on Statin intolerance: a new definition and key considerations for ASCVD risk reduction in the Statin intolerant patient. J Clin Lipidol. 2022;16(4):361\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.068.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"1283_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","volume":"37","author":"SF Nielsen","year":"2016","unstructured":"Nielsen SF, Nordestgaard BG. Negative Statin-related news stories decrease Statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016;37(11):908\u201316. https:\/\/doi.org\/10.1093\/eurheartj\/ehv641.","journal-title":"Eur Heart J"},{"key":"1283_CR7","doi-asserted-by":"publisher","unstructured":"Beshir SA, Hussain N, Elnor AA, Said ASA. Umbrella review on Non-Statin Lipid-Lowering therapy. J Cardiovasc Pharmacol Therap. 2021;26(5):437\u201352. https:\/\/doi.org\/10.1177\/10742484211002943.","DOI":"10.1177\/10742484211002943"},{"issue":"9","key":"1283_CR8","doi-asserted-by":"publisher","first-page":"e007485","DOI":"10.1161\/circoutcomes.120.007485","volume":"14","author":"A Saeed","year":"2021","unstructured":"Saeed A, Zhu J, Thoma F, et al. Cardiovascular disease Risk-Based Statin utilization and associated outcomes in a primary prevention cohort: insights from a large health care network. Circ Cardiovasc Qual Outcomes. 2021;14(9):e007485. https:\/\/doi.org\/10.1161\/circoutcomes.120.007485.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1283_CR9","doi-asserted-by":"publisher","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-Cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2022;80(14):1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006. The newest recommendations from the American College of Cardiology for selecting non-statin therapies in high risk patients on a maximally tolerated statin who need additional LDL cholesterol lowering.","DOI":"10.1016\/j.jacc.2022.07.006"},{"key":"1283_CR10","doi-asserted-by":"publisher","unstructured":"\u2022 Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021; 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484. Newest European recommendations for adding non-statin therapies for high risk patients.","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"1283_CR11","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.S33664","author":"P Toth","year":"2012","unstructured":"Toth P, Phan, Dayspring T. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012. https:\/\/doi.org\/10.2147\/vhrm.S33664.","journal-title":"Vasc Health Risk Manag"},{"key":"1283_CR12","doi-asserted-by":"publisher","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","DOI":"10.1056\/NEJMoa1410489"},{"key":"1283_CR13","doi-asserted-by":"publisher","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of Lowering LDL cholesterol with Simvastatin plus Ezetimibe in patients with chronic kidney disease (Study of heart and renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(11)60739-3.","DOI":"10.1016\/s0140-6736(11)60739-3"},{"issue":"12","key":"1283_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1161\/circulationaha.118.039415","volume":"140","author":"Y Ouchi","year":"2019","unstructured":"Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe Lipid-Lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75). Circulation. 2019;140(12):992\u20131003. https:\/\/doi.org\/10.1161\/circulationaha.118.039415.","journal-title":"Circulation"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-pharmtox-011613-140025","volume":"54","author":"GD Norata","year":"2014","unstructured":"Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273\u201393. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-140025.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1283_CR16","doi-asserted-by":"publisher","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid Lowering therapy. World J Cardiol. 2017;9(2). https:\/\/doi.org\/10.4330\/wjc.v9.i2.76.","DOI":"10.4330\/wjc.v9.i2.76"},{"issue":"23","key":"1283_CR17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of Evolocumab. J Am Coll Cardiol. 2014;63(23):2531\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.018.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1283_CR18","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of Bococizumab in High-Risk patients. N Engl J Med. 2017;376(16):1527\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1701488.","journal-title":"N Engl J Med"},{"issue":"7","key":"1283_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41569-023-00979-8","volume":"21","author":"A Sarraju","year":"2024","unstructured":"Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024;21(7):487\u201397. https:\/\/doi.org\/10.1038\/s41569-023-00979-8.","journal-title":"Nat Rev Cardiol"},{"key":"1283_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ahj.2023.12.004","volume":"269","author":"EA Bohula","year":"2024","unstructured":"Bohula EA, Marston NA, Ruzza A, et al. Rationale and design of the effect of Evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J. 2024;269:179\u201390. https:\/\/doi.org\/10.1016\/j.ahj.2023.12.004.","journal-title":"Am Heart J"},{"issue":"1","key":"1283_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1609243.","journal-title":"N Engl J Med"},{"issue":"48","key":"1283_CR22","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","journal-title":"Eur Heart J"},{"issue":"16","key":"1283_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"1283_CR24","doi-asserted-by":"publisher","unstructured":"Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA Interference for Cholesterol Lowering: The Bench\u2010to\u2010Bedside Story of\u00a0Inclisiran. Journal of the American Heart Association. 2024; 13(6):e032031. https:\/\/doi.org\/10.1161\/JAHA.123.032031.","DOI":"10.1161\/JAHA.123.032031."},{"key":"1283_CR25","unstructured":"HPS-4\/TIMI 65\/ORION-4. A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease. In. Edited by The TSG, Novartis P; 2018."},{"key":"1283_CR26","unstructured":"Randomized A. Double-blind, Placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in High-risk primary prevention patients (VICTORION-1 PREVENT). In.; 2023."},{"issue":"1","key":"1283_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","volume":"17","author":"TT Chiou","year":"2023","unstructured":"Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a united States lipid clinic. J Clin Lipidol. 2023;17(1):73\u20137. https:\/\/doi.org\/10.1016\/j.jacl.2022.10.009.","journal-title":"J Clin Lipidol"},{"issue":"11","key":"1283_CR28","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1803917.","journal-title":"N Engl J Med"},{"key":"1283_CR29","doi-asserted-by":"publisher","unstructured":"\u2022 Nissen SE, Lincoff AM, Brennan D et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. New England Journal of Medicine. 2023; 388(15):1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024. This randomized trial evaluated the efficacy and safety of bempedoic acid compared to placebo in statin-intolerant patients with or at high risk for cardiovascular disease. The study demonstrated that bempedoic acid significantly reduced LDL cholesterol levels and lowered the risk of cardiovascular events.","DOI":"10.1056\/NEJMoa2215024."},{"key":"1283_CR30","doi-asserted-by":"publisher","unstructured":"\u2022 Nissen SE, Menon V, Nicholls SJ et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023; 330(2):131\u2013140. https:\/\/doi.org\/10.1001\/jama.2023.9696. A subgroup analysis of the original study, demonstrating that in high risk primary prevention population, bempedoic acid therapy was associated with a significant reduction in major adverse cardiovascular events.","DOI":"10.1001\/jama.2023.9696"},{"issue":"18","key":"1283_CR31","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated Statins on Low-Density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138. https:\/\/doi.org\/10.1001\/jama.2019.16585.","journal-title":"JAMA"},{"issue":"2","key":"1283_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","volume":"84","author":"AM Lincoff","year":"2024","unstructured":"Lincoff AM, Ray KK, Sasiela WJ, et al. Comparative cardiovascular benefits of bempedoic acid and Statin drugs. J Am Coll Cardiol. 2024;84(2):152\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.048.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1283_CR33","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus Ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated Statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603. https:\/\/doi.org\/10.1177\/2047487319864671.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"1283_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"3","key":"1283_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","author":"The Lipid Research Clinics Coronary Primary","year":"1984","unstructured":"The Lipid Research Clinics Coronary Primary. Prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351\u201364. https:\/\/doi.org\/10.1001\/jama.1984.03340270029025.","journal-title":"JAMA"},{"issue":"10","key":"1283_CR36","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/cs-2020-0490","volume":"26","author":"Y Handelsman","year":"2020","unstructured":"Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm\u2013\u20092020 executive summary. Endocr Pract. 2020;26(10):1196\u2013224. https:\/\/doi.org\/10.4158\/cs-2020-0490.","journal-title":"Endocr Pract"},{"issue":"23","key":"1283_CR37","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1161\/01.cir.103.23.2828","volume":"103","author":"H Bloomfield Rubins","year":"2001","unstructured":"Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Circulation. 2001;103(23):2828\u201333. https:\/\/doi.org\/10.1161\/01.cir.103.23.2828.","journal-title":"Circulation"},{"key":"1283_CR38","doi-asserted-by":"publisher","unstructured":"Frick M.H, Elo O, Haapa K, et al. Helsinki heart study: Primary-Prevention trial with gemfibrozil in Middle-Aged men with dyslipidemia. N Engl J Med. 1987;317(20):1237\u201345. https:\/\/doi.org\/10.1056\/NEJM198711123172001.","DOI":"10.1056\/NEJM198711123172001."},{"key":"1283_CR39","doi-asserted-by":"publisher","unstructured":"Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362(17):1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","DOI":"10.1056\/NEJMoa1001282."},{"key":"1283_CR40","doi-asserted-by":"publisher","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term Fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(05)67667-2.","DOI":"10.1016\/s0140-6736(05)67667-2"},{"key":"1283_CR41","doi-asserted-by":"publisher","unstructured":"Pradhan AD, Glynn RJ, Fruchart J-C, et al. Triglyceride Lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645.","DOI":"10.1056\/NEJMoa2210645"},{"issue":"12","key":"1283_CR42","first-page":"826","volume":"40","author":"MK Ito","year":"2015","unstructured":"Ito MK. A comparative overview of prescription Omega-3 fatty acid products. P T. 2015;40(12):826\u201357.","journal-title":"P T"},{"key":"1283_CR43","doi-asserted-by":"publisher","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart association\/american college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","DOI":"10.1161\/CIR.0000000000001168"},{"key":"1283_CR44","doi-asserted-by":"publisher","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent Ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","DOI":"10.1056\/NEJMoa1812792"},{"issue":"22","key":"1283_CR45","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-Dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"7","key":"1283_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1001\/archinte.164.7.697","volume":"164","author":"J McKenney","year":"2004","unstructured":"McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164(7):697\u2013705. https:\/\/doi.org\/10.1001\/archinte.164.7.697.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1283_CR47","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","volume":"61","author":"PM Lavigne","year":"2013","unstructured":"Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.030.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1283_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jacc.2024.05.027","volume":"84","author":"MS Safarova","year":"2024","unstructured":"Safarova MS, Moriarty PM, Kullo IJ, Ballantyne CM, Gianos E. Bempedoic acid falls in line. J Am Coll Cardiol. 2024;84(2):163\u20134. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.027.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1283_CR49","doi-asserted-by":"publisher","first-page":"e011765","DOI":"10.1161\/jaha.118.011765","volume":"8","author":"CK Bradley","year":"2019","unstructured":"Bradley CK, Wang TY, Li S, et al. Patient-Reported reasons for declining or discontinuing Statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765. https:\/\/doi.org\/10.1161\/jaha.118.011765.","journal-title":"J Am Heart Assoc"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01283-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01283-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01283-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T07:02:30Z","timestamp":1743750150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01283-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01283-1","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"25 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies included in this review are published and followed ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Dr. Karalis has received research grant support from Amgen, Regeneron, and Novartis, is a consultant for Esperion and Novartis, and is on the speaker\u2019s bureau for Novartis, Esperion, and Amgen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"46"}}